Sexual Well-Being in Adult Male Patients with Congenital Adrenal Hyperplasia
Table 1
Clinical and genetic characteristics of 20 male patients with 21-OHD at study start (baseline).
Pat. no.
Pheno-type
Genotype
Mutation group
Age (yr)
BMI (kg/m2)
Height (cm)
GC dose equivalent/m2 BSA (mg/m2)
FC dose/m2 BSA (g/m2)
B02
SW
I2G/I172N
B
23
19.0
178
14.52
58.07
B06
SW
I2G + P453/I2G + P453S
B
24
23.0
164
22.29
63.69
B09
SW
V281L/del + V281L
nc
18
16.5
171
33.33
66.67
B10
SW
I172N/I172N
B
18
26.0
170
15.79
52.63
B12
SW
I2G/I2G
A
32
28.0
184
19.91
88.50
B14
SW
I2G/del
A
25
27.5
177
14.63
48.78
B15
SW
I2G/I2G
A
21
26.5
163
19.44
55.56
B16
SW
I2G/del
A
23
25.0
170
27.78
55.56
B17
SW
I2G/del
A
20
30.0
171
26.83
48.78
B18
SW
I172/del
B
49
25.0
155
20.22
37.37
B20
SW
nd
18
20.0
174
13.24
58.82
B07
SW
del/R356W
Null
23
28.0
172
17.68
50.50
B08
SW
I2G-V281L/del-V281L
A
29
25.5
160
13.24
58.86
B22
SW
I2G/E6 cluster
A
23
25.0
180
20.0
50.00
B01
SV
I2G/I172G
B
42
36.0
158
10.01
B03
SV
I172N/I172N + del
B
47
27.0
153
16.68
B04
SV
I2G/172N
B
42
24.0
153
19.61
B13
SV
I172N/Q318X + V281L
B
26
38.0
172
20.30
B19
SV
I172N/del
B
47
30.0
162
19.95
B21
SV
I2G/I172N
B
28
24.0
164
22.59
SW Mean ± SD
24.7 ± 8.1
24.6 ± 3.8
170.6 ± 8.0
19.92 ± 5.97
56.70 ± 11.68
SV Mean ± SD
38.7 ± 9.3
29.8 ± 6.0
160.3 ± 3.0
18.19 ± 4.43
All CAH Mean ± SD
28.9 ± 10.5
26.2 ± 5.0
167.6 ± 9.0
19.40 ± 5.50
SW: classical salt wasting; SV: classical simple virilizing; BMI: body mass index; BSA: body surface area; FC: fludrocortisone. The dose of daily glucocorticoid (GC) was converted into milligrams of daily hydrocortisone equivalent (1 mg dexamethasone = 14 mg prednisolone = 70 mg hydrocortisone). Mutation grouping was done according to Krone et al. [30]; nc: not classified; nd: not done.
